TGen teams with Agilent Labs on cancer genetics
Summary:
The Translational Genomics Research Institute has announced that it is collaborating with California-based research firm Agilent Laboratories to further develop a method to more rapidly diagnose and treat some forms of cancer.
Full Story:
The Translational Genomics Research Institute has announced that it is collaborating with California-based research firm Agilent Laboratories to further develop a method to more rapidly diagnose and treat some forms of cancer.
The method, called comparative genomic hybridization (CGH), provides researchers with a means of identifying sections of chromosomes that have been lost or have multiplied in cancer cells — ways in which tumors escape normal growth controls.
"The ability to closely analyze and view gene expression and high-resolution CGH data side by side could yield unprecedented insights into the nature of various cancers," Jeff Trent, president and scientific director of TGen, told the Business Journal. "In addition to shedding light on how tumors arise, these data could provide the foundation for diagnostic and prognostic tools and help identify the most promising targets for drug development."
For more information:
"TGen, Agilent Labs to combine on cancer genetics project," Business Journal, 06/08/2004